肺癌患者应用吉西他滨联合紫杉醇治疗的临床效果
|
摘要
目的探讨分析肺癌患者应用吉西他滨联合紫杉醇治疗的临床效果。方法选取2017年3月～2018年3月我院收治的92例肺癌患者作为研究对象,按照随机数字表法将其分为对照组(46例)和研究组(46例)。对照组患者采用吉西他滨联合顺铂方案治疗,研究组患者采用吉西他滨联合紫杉醇方案治疗。比较两组患者的治疗总有效率、肺功能影响以及不良反应发生情况。结果研究组患者的治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗前,两组患者的第1秒呼气容积(FEV_1)、FEV_1百分比(FEV_1%)和FEV_1与肺活量(FVC)之间的比值(FEV_1/FVC)等肺功能指标水平比较,差异无统计学意义(P>0.05),治疗后,两组患者的上述肺功能指标水平均高于本组治疗前,且研究组显著高于对照组,差异有统计学意义(P<0.05)。治疗后,研究组患者的肝功能损害、脱发、骨髓抑制、周围神经毒性等不良反应发生率及总发生率均显著低于对照组,差异有统计学意义(P<0.05)。结论肺癌患者应用吉西他滨联合紫杉醇治疗,治疗效果显著,对患者的肺功能影响较小,且不良反应发生率低,值得推广使用。
Objective To investigate and analyze the clinical effect of Gemcitabine combined with Paclitaxel in patients with lung cancer. Methods Ninety-two patients with lung cancer admitted to our hospital from March 2017 to March2018 were selected as the study subjects. They were divided into control group(46 cases) and study group(46 cases)according to random number table method. The control group was treated with Gemcitabine combined with Cisplatin,and the study group was treated with Gemcitabine combined with Paclitaxel. The total effective rate, pulmonary function and adverse reactions were compared between the two groups. Results The total effective rate of the study group was higher than that of the control group, the difference was statistically significant(P<0.05). There was no significant difference in lung function indexes such as forced expiratory volume in 1 s(FEV_1), FEV_1 percentage(FEV_1%) and the ratio of FEV_1 to forced vital capacity(FVC)(FEV_1/FVC) between the two groups before treatment(P>0.05). After treatment, the above lung function indexes of the two groups were higher than those before treatment, and the study group was significantly higher than the control group, with statistically significant difference(P<0.05). After treatment, the incidence of liver function damage, alopecia, bone marrow suppression, peripheral neurotoxicity and the total incidence of adverse reaction in the study group were significantly lower than those in the control group(P<0.05). Conclusion Gemcitabine combined with Paclitaxel in the treatment of lung cancer has significant therapeutic effect, less impact on pulmonary function, and low incidence of adverse reactions, which is worthy of promotion.
Objective To investigate and analyze the clinical effect of Gemcitabine combined with Paclitaxel in patients with lung cancer. Methods Ninety-two patients with lung cancer admitted to our hospital from March 2017 to March2018 were selected as the study subjects. They were divided into control group(46 cases) and study group(46 cases)according to random number table method. The control group was treated with Gemcitabine combined with Cisplatin,and the study group was treated with Gemcitabine combined with Paclitaxel. The total effective rate, pulmonary function and adverse reactions were compared between the two groups. Results The total effective rate of the study group was higher than that of the control group, the difference was statistically significant(P<0.05). There was no significant difference in lung function indexes such as forced expiratory volume in 1 s(FEV_1), FEV_1 percentage(FEV_1%) and the ratio of FEV_1 to forced vital capacity(FVC)(FEV_1/FVC) between the two groups before treatment(P>0.05). After treatment, the above lung function indexes of the two groups were higher than those before treatment, and the study group was significantly higher than the control group, with statistically significant difference(P<0.05). After treatment, the incidence of liver function damage, alopecia, bone marrow suppression, peripheral neurotoxicity and the total incidence of adverse reaction in the study group were significantly lower than those in the control group(P<0.05). Conclusion Gemcitabine combined with Paclitaxel in the treatment of lung cancer has significant therapeutic effect, less impact on pulmonary function, and low incidence of adverse reactions, which is worthy of promotion.
引文
[1]李斌.晚期胰腺癌患者应用吉西他滨联合替吉奥治疗的临床效果评价[J].临床和实验医学杂志,2016,15(8):771-773.
[2]宋文灿,鲍瑜,钱江,等.恩度联合吉西他滨和顺铂治疗晚期肺鳞癌的临床疗效及对患者生活质量的影响[J].实用癌症杂志,2018,11(1):59-62.
[3]权瑞泉,熊明兰.吉西他滨联合顺铂治疗肺癌术后患者的疗效及影响因素[J].中国肿瘤临床与康复,2017,18(7):807-810.
[4]穆晓攀,杜晓明,张泽群,等.吉西他滨联合顺铂与紫杉醇联合顺铂方案治疗晚期肺鳞癌的临床疗效及不良反应观察[J].癌症进展,2016,14(4):384-386.
[5]罗建华,李俏俏,潘君素.吉西他滨联合长春瑞滨治疗紫杉醇耐药的晚期老年非小细胞肺癌疗效观察[J].药物流行病学杂志,2017,48(1):10-12.
[6]孔斌.不同含铂治疗方案在晚期非小细胞肺癌患者中的应用效果[J].中国医药导报,2016,13(35):102-105.
[7]牛荣,刘玉华,刘喜婷,等.乌苯美司联合紫杉醇与顺铂治疗晚期非小细胞肺癌的疗效及对患者免疫功能的影响[J].现代生物医学进展,2016,16(6):1147-1149.
[8]Ridolfi R.Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer:results of a phaseⅡ~Ⅲstudy[J].J Clin Oncol,2016,24(4):681-687.
[9]谢忠海,沈琦斌,李鸿伟,等.多西紫杉醇联合吉西他滨和顺铂治疗非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(11):972-974.
[10]王磊,李飞,黄晓日,等.吉西他滨联合顺铂化疗对非小细胞肺癌患者肿瘤标志物的影响[J].中国肿瘤临床与康复,2017,45(4):408-410.
[11]王继贤.紫杉醇脂联合顺铂与替吉奥联合顺铂在晚期非小细胞肺癌患者中的应用效果对比[J].癌症进展,2016,14(3):272-273.
[12]陈玲玲,林勇,叶小凯,等.血清CEA、CYFRA21-1及TSGF在肺癌化疗前后的表达变化及意义[J].实用癌症杂志,2017,32(12):1928-1930.
[13]马晓惠,任彩红,黄彩霞,等.吉西他滨与放疗联合应用治疗老年中晚期宫颈癌30例的临床疗效分析[J].实用癌症杂志,2017,32(9):1534-1536.
[14]杨静欢,刘晓黎,吕倩,等.卡铂联合吉西他滨每周给药治疗晚期非小细胞肺癌的临床疗效观察[J].现代肿瘤医学,2016,24(15):2410-2412.
[15]Yakisich JS,O′Doherty GA,Iyer AKV.Digitoxin and its synthetic analog Monod have potent antiproliferative effects on lung cancer cells and potentiate the effects of hydroxyurea and paclitaxel[J].Oncol Rep,2016,35(2):878-886.
[2]宋文灿,鲍瑜,钱江,等.恩度联合吉西他滨和顺铂治疗晚期肺鳞癌的临床疗效及对患者生活质量的影响[J].实用癌症杂志,2018,11(1):59-62.
[3]权瑞泉,熊明兰.吉西他滨联合顺铂治疗肺癌术后患者的疗效及影响因素[J].中国肿瘤临床与康复,2017,18(7):807-810.
[4]穆晓攀,杜晓明,张泽群,等.吉西他滨联合顺铂与紫杉醇联合顺铂方案治疗晚期肺鳞癌的临床疗效及不良反应观察[J].癌症进展,2016,14(4):384-386.
[5]罗建华,李俏俏,潘君素.吉西他滨联合长春瑞滨治疗紫杉醇耐药的晚期老年非小细胞肺癌疗效观察[J].药物流行病学杂志,2017,48(1):10-12.
[6]孔斌.不同含铂治疗方案在晚期非小细胞肺癌患者中的应用效果[J].中国医药导报,2016,13(35):102-105.
[7]牛荣,刘玉华,刘喜婷,等.乌苯美司联合紫杉醇与顺铂治疗晚期非小细胞肺癌的疗效及对患者免疫功能的影响[J].现代生物医学进展,2016,16(6):1147-1149.
[8]Ridolfi R.Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer:results of a phaseⅡ~Ⅲstudy[J].J Clin Oncol,2016,24(4):681-687.
[9]谢忠海,沈琦斌,李鸿伟,等.多西紫杉醇联合吉西他滨和顺铂治疗非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(11):972-974.
[10]王磊,李飞,黄晓日,等.吉西他滨联合顺铂化疗对非小细胞肺癌患者肿瘤标志物的影响[J].中国肿瘤临床与康复,2017,45(4):408-410.
[11]王继贤.紫杉醇脂联合顺铂与替吉奥联合顺铂在晚期非小细胞肺癌患者中的应用效果对比[J].癌症进展,2016,14(3):272-273.
[12]陈玲玲,林勇,叶小凯,等.血清CEA、CYFRA21-1及TSGF在肺癌化疗前后的表达变化及意义[J].实用癌症杂志,2017,32(12):1928-1930.
[13]马晓惠,任彩红,黄彩霞,等.吉西他滨与放疗联合应用治疗老年中晚期宫颈癌30例的临床疗效分析[J].实用癌症杂志,2017,32(9):1534-1536.
[14]杨静欢,刘晓黎,吕倩,等.卡铂联合吉西他滨每周给药治疗晚期非小细胞肺癌的临床疗效观察[J].现代肿瘤医学,2016,24(15):2410-2412.
[15]Yakisich JS,O′Doherty GA,Iyer AKV.Digitoxin and its synthetic analog Monod have potent antiproliferative effects on lung cancer cells and potentiate the effects of hydroxyurea and paclitaxel[J].Oncol Rep,2016,35(2):878-886.